What is the price target for UPB stock?
12 analysts have analysed UPB and the average price target is 44.37 USD. This implies a price increase of 349.09% is expected in the next year compared to the current price of 9.88.
NASDAQ:UPB • US91678A1079
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for UPSTREAM BIO INC (UPB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-27 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2025-12-18 | Mizuho | Initiate | Outperform |
| 2025-12-02 | LifeSci Capital | Initiate | Outperform |
| 2025-11-18 | Evercore ISI Group | Initiate | Outperform |
| 2025-10-14 | Truist Securities | Initiate | Buy |
| 2024-11-05 | TD Cowen | Initiate | Buy |
| 2024-11-05 | William Blair | Initiate | Outperform |
| 2024-11-05 | JP Morgan | Initiate | Overweight |
| 2024-11-05 | Piper Sandler | Initiate | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.38M 96.37% | 2.37M -0.42% | 2.854M 20.42% | 1.507M -47.20% | 1.719M 14.07% | 5.729M 233.28% | 8.507M 48.49% | 92.697M 989.66% | 239.57M 158.44% | 463.61M 93.52% | 842.56M 81.74% | |
| EBITDA YoY % growth | -40.054M -67.58% | -77.675M -93.93% | -160.173M -106.21% | -183.82M -14.76% | -200.99M -9.34% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -40.114M -67.78% | -77.764M -93.86% | -160.361M -106.21% | -199.783M -24.58% | -216.822M -8.53% | -296.948M -36.95% | -260.872M 12.15% | -229.971M 11.85% | -114.72M 50.12% | 59.985M 152.29% | 368.83M 514.87% | |
| Operating Margin | -1,685.46% | -3,281.18% | -5,618.82% | -13,256.99% | -12,613.28% | -5,183.24% | -3,066.55% | -248.09% | -47.89% | 12.94% | 43.77% | |
| EPS YoY % growth | N/A | N/A | -2.67 67.12% | -3.00 -12.69% | -3.24 -7.96% | -3.58 -10.44% | -4.01 -11.99% | -3.62 9.76% | -1.55 57.20% | 1.20 177.61% | 5.43 352.10% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.78 -53.15% | -0.79 -6.46% | -0.72 -14.63% | -0.72 7.79% | -0.90 -15.09% | -0.95 -20.51% | -0.98 -36.36% | -1.06 -46.51% |
| Revenue Q2Q % growth | 446.42K -21.13% | 446.42K -52.36% | 448.44K -34.34% | 468.64K -29.84% | 747.4K 67.42% | 747.4K 67.42% | 757.5K 68.92% | 767.6K 63.79% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -45.998M -43.69% | -47.348M -6.77% | -48.246M -27.52% | -49.279M -6.74% | N/A | N/A | N/A | N/A |
All data in USD
12 analysts have analysed UPB and the average price target is 44.37 USD. This implies a price increase of 349.09% is expected in the next year compared to the current price of 9.88.
UPSTREAM BIO INC (UPB) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of UPSTREAM BIO INC (UPB) is -0.78 USD and the consensus revenue estimate is 446.42K USD.
The expected long term growth rate for UPSTREAM BIO INC (UPB) is 27.04%.